Prospective phenotyping of CHAMP1 disorder indicates that coding mutations may not act through haploinsufficiency
- PMID: 37454340
- PMCID: PMC10449971
- DOI: 10.1007/s00439-023-02578-6
Prospective phenotyping of CHAMP1 disorder indicates that coding mutations may not act through haploinsufficiency
Abstract
CHAMP1 disorder is a genetic neurodevelopmental condition caused by mutations in the CHAMP1 gene that result in premature termination codons. The disorder is associated with intellectual disability, medical comorbidities, and dysmorphic features. Deletions of the CHAMP1 gene, as part of 13q34 deletion syndrome, have been briefly described with the suggestion of a milder clinical phenotype. To date, no studies have directly assessed differences between individuals with mutations in CHAMP1 to those with deletions of the gene. We completed prospective clinical evaluations of 16 individuals with mutations and eight with deletions in CHAMP1. Analyses revealed significantly lower adaptive functioning across all domains assessed (i.e., communication, daily living skills, socialization, and motor skills) in the mutation group. Developmental milestones and medical features further showed difference between groups. The phenotypes associated with mutations, as compared to deletions, indicate likely difference in pathogenesis between groups, where deletions are acting through CHAMP1 haploinsufficiency and mutations are acting through dominant negative or gain of function mechanisms, leading to a more severe clinical phenotype. Understanding this pathogenesis is important to the future of novel therapies for CHAMP1 disorder and illustrates that mechanistic understanding of mutations must be carefully considered prior to treatment development.
© 2023. The Author(s).
Conflict of interest statement
T.L is on the Scientific Advisory Board for the CHAMP1 Foundation. A.K. is on the Advisory Board for the Klingenstein Third Generation Foundation, Ovid Therapeutics, David Lynch Foundation, ADNP Kids Research Foundation, and Ritrova Therapeutics and consults to Acadia, Alkermes, Jaguar Therapeutics, GW Pharmaceuticals, Neuren Pharmaceuticals, Scioto Biosciences, and Biogen. P.M.S. consults to Deerfield. J.D.B. consults to BridgeBio and to Rumi, holds a patent for IGF-1 in Phelan-McDermid syndrome, holds an honorary professorship from Aarhus University Denmark, receives research support from Takeda and Oryzon, and is a journal editor for Springer Nature. The other authors declare no financial interests.
Figures
References
-
- Aman MG, Singh N. Aberrant Behavior Checklist. Community (ABC): Slosson Educational Publications; 1994.
-
- Fenson L. MacArthur-Bates communicative development inventories: Paul H. MD: Brookes Publishing Company Baltimore; 2007.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
